Table 2.
Effects of bariatric surgery on body composition, calcitropic hormones and bone turnover markers in the 12 months after either RYGB or SG
| Variable | Treatment | Baseline | 12 months | Delta 12 months % change | p-value within group | p-value between groups at 12 months |
|---|---|---|---|---|---|---|
| Weight (kg) | RYGB | 118.6 ± 15.2 | 67.5 ± 35.8 | −30.1 ± 7.6 | <0.001 | 0.228 |
| SG | 113.7 ± 17.6 | 85.7 ± 20.3 | −25.0 ± 10.1 | <0.001 | ||
| BMI (kg/m2) | RYGB | 44.1 ± 5.1 | 31.2 ± 4.8 | −29.6 ± 7.6 | <0.001 | 0.372 |
| SG | 43.7 ± 5.9 | 32.6 ± 7.2 | −25.5 ± 11.2 | <0.001 | ||
| Visceral adipose tissue (cm2) | RYGB | 207.8 ± 104.4 | 121.7 ± 80.1 | −44.8 ± 17.5 | <0.001 | 0.895 |
| SG | 203.8 ± 111.9 | 109.0 ± 70.4 | −43.2 ± 29.5 | 0.002 | ||
| Subcutaneous adipose tissue (cm2) | RYGB | 463.9 ± 123.4 | 261.4 ± 117.0 | −45.9 ± 19.0 | <0.001 | 0.922 |
| SG | 502.3 ± 103.5 | 344.1 ± 209.8 | −47.1 ± 24.9 | 0.002 | ||
| Serum calcium (mg/dl) | RYGB | 9.5 ± 0.5 | 9.4 ± 0.3 | −1.8 ± 4.9 | 0.312 | 0.423 |
| SG | 9.6 ± 0.5 | 9.6 ± 0.3 | 0.2 ± 5.5 | 0.911 | ||
| Serum 25-hydoxyvitamin D (ng/ml) | RYGB | 25.5 ± 5.7 | 29.1 ± 11.2 | 12.3 ± 35.9 | 0.333 | 0.231 |
| SG | 31.2 ± 12.7 | 41.7 ± 16.1 | 48.3 ± 82.1 | 0.096 | ||
| Serum PTH (pg/ml) | RYGB | 51.1 ± 16.1 | 50.4 ± 14.4 | −3.8 ± 20.8 | 0.595 | 0.909 |
| SG | 62.9 ± 33.9 | 52.2 ± 19.6 | −5.7 ± 42.9 | 0.687 | ||
| P1NP (ng/ml) | RYGB | 50.6 ± 21.9 | 105.3 ± 33.2 | 117.0 ± 64.5 | <0.001 | 0.035 |
| SG | 61.1 ± 26.3 | 91.6 ± 36.9 | 56.9 ± 49.4 | 0.005 | ||
| CTX (ng/ml) | RYGB | 0.38 ± 0.1 | 0.99 ± 0.31 | 158.9 ± 43.3 | <0.001 | 0.211 |
| SG | 0.49 ± 0.2 | 0.94 ± 0.4 | 106.8 ± 115.7 | 0.017 |
RYGB: Roux-en-Y gastric bypass, SG: sleeve gastrectomy; PTH: parathyroid hormone, P1NP: procollagen type 1 N-terminal propeptide; CTX: collagen type 1 cross-linked C-telopeptide